Zydus Cadila gets USFDA nod for its ulcerative colitis drug

The company has received final approval from the USFDA for Mesalamine delayed-release tablets in the strength of 800 mg, Zydus Cadila said in a statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news